0000000000358618

AUTHOR

Ivo Barić

showing 4 related works from this author

Mortality and cause of death in mucopolysaccharidosis type II-a historical review based on data from the Hunter Outcome Survey (HOS).

2009

Mucopolysaccharidosis type II (MPS II or Hunter syndrome) is a progressive, multisystemic disease caused by a deficiency of iduronate-2-sulfatase. Patients with the severe form of the disease have cognitive impairment and typically die in the second decade of life. Patients with the less severe form do not experience significant cognitive involvement and may survive until the fifth or sixth decade of life. We studied the relationship of both severity of MPS II and the time period in which patients died with age at death in 129 patients for whom data were entered retrospectively into HOS (Hunter Outcome Survey), the only large-scale, multinational observational study of patients with MPS II.…

AdultMalemedicine.medical_specialtyPediatricsAdolescentIdursulfaseIduronate SulfataseCohort StudiesYoung AdultCause of DeathEpidemiologyGeneticsmedicineHumansMucopolysaccharidosis type IIYoung adultChildGenetics (clinical)Cause of deathMucopolysaccharidosis IIRetrospective StudiesMPS type IIbusiness.industryData CollectionAge FactorsInfantHunter syndromeEnzyme replacement therapymedicine.diseaseSurgeryTreatment OutcomeChild PreschoolFemaleSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drugCohort studyJournal of inherited metabolic disease
researchProduct

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency

2015

BackgroundLysosomal acid lipase is an essential lipid-metabolizing enzyme that breaks down endocytosed lipid particles and regulates lipid metabolism. We conducted a phase 3 trial of enzyme-replacement therapy in children and adults with lysosomal acid lipase deficiency, an underappreciated cause of cirrhosis and severe dyslipidemia. MethodsIn this multicenter, randomized, double-blind, placebo-controlled study involving 66 patients, we evaluated the safety and effectiveness of enzyme-replacement therapy with sebelipase alfa (administered intravenously at a dose of 1 mg per kilogram of body weight every other week); the placebo-controlled phase of the study was 20 weeks long and was followe…

AdultMalemedicine.medical_specialtyCirrhosisAdolescentHDLBiopsy[SDV]Life Sciences [q-bio]Lysosomal acid lipase deficiencyGastroenterologyLDLlaw.inventionYoung Adultchemistry.chemical_compoundDouble-Blind MethodRandomized controlled triallawInternal medicinemedicineHumansAdolescent; Adult; Aged; Alanine Transaminase; Biopsy; Child; Child Preschool; Cholesterol HDL; Cholesterol LDL; Double-Blind Method; Dyslipidemias; Female; Humans; Liver; Male; Middle Aged; Sterol Esterase; Wolman Disease; Young AdultChildPreschoolComputingMilieux_MISCELLANEOUSAgedDyslipidemiasbiologyCholesterolbusiness.industryWolman DiseaseAlanine TransaminaseLipid metabolismGeneral MedicineMiddle AgedSterol Esterasemedicine.disease3. Good healthCholesterolEndocrinologyLiverSebelipase alfachemistryAlanine transaminasebiology.proteinFemalebusinessDyslipidemia
researchProduct

Abnormal Hypermethylation at Imprinting Control Regions in Patients with S-Adenosylhomocysteine Hydrolase (AHCY) Deficiency

2016

S-adenosylhomocysteine hydrolase (AHCY) deficiency is a rare autosomal recessive disorder in methionine metabolism caused by mutations in the AHCY gene. Main characteristics are psychomotor delay including delayed myelination and myopathy (hypotonia, absent tendon reflexes etc.) from birth, mostly associated with hypermethioninaemia, elevated serum creatine kinase levels and increased genome wide DNA methylation. The prime function of AHCY is to hydrolyse and efficiently remove S-adenosylhomocysteine, the by-product of transmethylation reactions and one of the most potent methyltransferase inhibitors. In this study, we set out to more specifically characterize DNA methylation changes in blo…

Male0301 basic medicineMethyltransferaselcsh:MedicineArtificial Gene Amplification and ExtensionGlycine N-MethyltransferaseBiochemistryPolymerase Chain Reactionlaw.inventionMethionine0302 clinical medicinelawAmino Acidslcsh:SciencePolymerase chain reactionGeneticsDNA methylationMammalian GenomicsMultidisciplinaryOrganic CompoundsGenomicsMethylationChromatinEnzymes3. Good healthNucleic acidsChemistryPhysical SciencesDNA methylationEpigeneticsFemaleDNA modificationChromatin modificationResearch ArticleChromosome biologyCell biologyAlu elementBiologyResearch and Analysis MethodsGenomic Imprinting03 medical and health sciencesAlu ElementsGeneticsSulfur Containing Amino AcidsHumansRepeated SequencesMolecular Biology TechniquesMolecular BiologyAmino Acid Metabolism Inborn ErrorsGeneBiology and life sciencesOrganic Chemistrylcsh:RChemical CompoundsInfant NewbornProteinsInfantDNAMethyltransferasesCreatineMolecular biologyLong Interspersed Nucleotide Elements030104 developmental biologyDifferentially methylated regionsAnimal GenomicsEnzymologyAHCY ; Hypermethylationlcsh:QGene expressionGenomic imprinting030217 neurology & neurosurgeryDevelopmental BiologyPLOS ONE
researchProduct

P1211 : Efficacy and safety of sebelipase alfa in children and adults with lysosomal acid lipase deficiency: Results of a phase 3 trial

2015

HepatologyBiochemistrySebelipase alfabusiness.industrymedicineLysosomal acid lipase deficiencyPharmacologymedicine.diseasebusinessJournal of Hepatology
researchProduct